Delivery service continues to expand across the State
TORONTO, Nov. 21, 2017 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCBB: LHSIF) ("Liberty" or the "Company") announced today that it has secured locations for two additional medical cannabis dispensaries in the State of Florida that are scheduled to open in early 2018. The new dispensaries, located in St. Petersburg and Port St. Lucie, will be opened in addition to the two previously announced locations in The Villages and Fort Lauderdale. The dispensary operations and plans are being finalized and will be submitted to the Florida Department of Health, Office of Medical Marijuana Use for approval in accordance with state law.
The registered patient count in Florida continues to increase rapidly with approximately 51,000 patients registered with the State currently. This number is expected to continue to grow as more physicians recommend cannabis as a treatment option and as more Florida residents become educated on the benefits of medical cannabis to treat certain qualifying conditions. Liberty's expansion represents yet another important step in the Company's plans to offer convenient accessibility of medical cannabis to the increasing number of patients in Florida, regardless of their geographic location.
"Our dispensary locations are strategic by design," said George Scorsis, Director and CEO of Liberty. "We follow a strict geographic targeting methodology focusing on locations with a substantial population and a significant number of prescribing physicians. Liberty expects to expand the dispensary footprint aggressively over the next few months. The Villages location is on track to open in December and the Fort Lauderdale in January 2018."
In yet another initiative in Liberty's quest to increase timely accessibility to medical cannabis across the State, additional delivery vehicles have also been added to facilitate direct to home delivery. Liberty is committed to ensuring that patients have convenient and timely access to its high-quality, clean and safe pharmaceutical grade medical cannabis when patients need it the most.
"Our aggressively expanding footprint and more robust delivery offering is yet another way in which Liberty is ensuring that patients have the best access possible to our medical cannabis products and as we grow our business we are committed to ensuring that more and more of these access points are added to our roster of services for patients in need," continued Scorsis. "Additionally, our patient-centric dispensaries, named Cannabis Education Centers, will provide comprehensive education and resources to inform patients on cannabis use as a safe alternative to treat symptoms related to several medical ailments."
About the new dispensary locations:
St. Petersburg is located on the west coast of Florida with a population of 260,000 people and lies adjacent to Tampa. The medical demographics provide a large patient pool to whom Liberty may provide its high-quality medical cannabis products.
Port St. Lucie
Port St. Lucie is located on the east coast of Florida and has been one of the fastest growing areas in the State over the last few years. Today the population is around 190,000 offering Liberty a large and growing patient pool.
For more information on Liberty please visit www.libertyhealthsciences.com.
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. ("Liberty") is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's future expansion and growth strategies, the Company's intentions to open dispensary locations in various regions in Florida and the Company's expectations in respect of the future growth of medical cannabis as a treatment option in Florida. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
For further information: For Canadian media inquiries, please contact: Matt Salvatore, Edelman, (613) 315-7362, [email protected]; For U.S. media inquiries, please contact: David Schull or Nic Johnson, Russo Partners, (858) 717-2310, [email protected], [email protected]